The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.
 
Janet E. Murphy
Consulting or Advisory Role - Celgene; Merrimack
 
Jennifer Yon-Li Wo
No Relationships to Disclose
 
Cristina Ferrone
No Relationships to Disclose
 
Wenqing Jiang
No Relationships to Disclose
 
Beow Y. Yeap
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
No Relationships to Disclose
 
Eunice Lee Kwak
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen
 
Jill N. Allen
No Relationships to Disclose
 
Jeffrey W. Clark
No Relationships to Disclose
 
Jason Edward Faris
Employment - Novartis
 
Andrew X. Zhu
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Sanofi
Research Funding - Lilly (Inst)
 
Lipika Goyal
No Relationships to Disclose
 
Harvey J. Mamon
No Relationships to Disclose
 
Keith D Lillemoe
No Relationships to Disclose
 
David P. Ryan
Stock and Other Ownership Interests - MPM Capital
Honoraria - Research to Practice; UpToDate
Consulting or Advisory Role - MPM Capital
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties
 
Thomas F. DeLaney
No Relationships to Disclose
 
Carlos Fernandez-del Castillo
No Relationships to Disclose
 
Yves Boucher
No Relationships to Disclose
 
Theodore S. Hong
Research Funding - Novartis (Inst); Taiho Pharmaceutical